Genmab grants board 5,300 stock units for 2026
The RSUs vest on the first banking day of the month following a three-year period from the grant date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S shareholders at an Extraordinary General Meeting approved the Board of Directors’ 2026 remuneration proposal, including restricted stock units (RSUs). The approval resulted in 5,300 RSUs being granted to Board members under the company’s Remuneration Policy. Each RSU was awarded cost-free and gives its owner a conditional right to receive one Genmab A/S share with a nominal value of DKK 1. The fair value per RSU was DKK 2,487.00, equal to the share’s closing market price on the grant date. The RSUs vest on the first banking day of the month following a period of three years from the grant date and are subject to the Remuneration Policy and applicable RSU program.
Key Figures
Restricted stock units granted: 5,300 RSUs
Shares per restricted stock unit: 1 share
Fair value per restricted stock unit: DKK 2,487.00
+2 more
5 metrics
Restricted stock units granted
5,300 RSUs
Granted to Board members under the 2026 remuneration proposal
Shares per restricted stock unit
1 share
Conditional right provided by each RSU
Fair value per restricted stock unit
DKK 2,487.00
Equal to the closing market price of one Genmab A/S share on the grant date
Nominal value per share
DKK 1
Share deliverable under each RSU
Vesting period
Three years
Vesting occurs on the first banking day of the month following the period
Key Terms
restricted stock units, fair value, vest, conditional right
4 terms
restricted stock units financial
"share-based remuneration in the form of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
fair value financial
"The fair value of each restricted stock unit"
Fair value is an estimate of what an asset or company is really worth today, derived from expected future earnings, comparable market prices and other relevant facts—like agreeing a price for a used car after checking mileage, condition and similar listings. Investors use fair value to decide whether a stock looks overpriced or undervalued, which helps guide buy, hold or sell decisions and sets expectations for potential returns and risk.
vest financial
"will vest on the first banking day"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
conditional right financial
"provides the owner with a conditional right"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many RSUs did Genmab (GMAB) grant to its Board members?
Genmab granted 5,300 restricted stock units to Board members under its 2026 remuneration proposal. Each unit was awarded cost-free and provides a conditional right to receive one Genmab A/S share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF OCTOBER 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated October 7, 2026 | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: October 7, 2026
Exhibit 99.1
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
Company Announcement
COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB)
Today, Genmab A/S held an Extraordinary General Meeting.
At the Extraordinary General Meeting the proposal from the Board of Directors on remuneration of the Board of Directors for 2026, including share-based remuneration in the form of restricted stock units, was approved.
As a result of the adoption of the proposal, a total of 5,300 restricted stock units were granted to the members of the Board of Directors in accordance with Genmab A/S’ Remuneration Policy.
Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price of one Genmab A/S share on the date of grant, DKK 2,487.00.
The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant and are otherwise subject to the terms and conditions set out in Genmab A/S’ Remuneration Policy and the applicable restricted stock unit program.
Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. Genmab's Remuneration Policy is accessible via this link Compensation | Genmab.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn, X, Facebook and Instagram.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 41 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 41 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||